Back to results
US 2013/0252986 A1Published application
Compounds
AssigneeGlaxo Group Limited
InventorsZehong Wan, Xiaomin Zhang, Jian Wang, Cheng Peng, Yun Jin, Yimin Hu
Life of this patent
Estimating the term…
Abstract
The present invention relates to novel compounds that inhibit Lp-PLA2 activity, processes for their preparation, to compositions containing them and to their use in the treatment of diseases associated with the activity of Lp-PLA2, for example atherosclerosis, Alzheimer's disease and/or diabetic macular edema.
Claims14
A compound of Formula (I) or a pharmaceutically acceptable salt thereof
- wherein:
- A is N or CH;
- n is 1 or 2;
- when A is N, Y Is absent, O or CH2 or when A is CH, Y is O;
- Z is H, C1-C3 Alkyl;
- —(C1-C3alkyl)-heteroaryl wherein said heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of C1-C3 alkyl and C1-C3alkoxyl;
- Ra is H, F, Cl, or C1-C3alkyl;
- Rb is phenyl or heteroaryl either of which is optionally substituted with one or more substituents independently selected from the group consisting of CN and halo;
- and
- Rc is phenyl or heteroaryl, wherein either of phenyl or heteroaryl is optionally substituted with one or more substituents independently selected from the group consisting of halo, C1-C3alkyl, and C1-C3haloalkyl.
7 more elements
14-15. (canceled)
Dependencies are inferred from the claim text.